These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16094557)

  • 21. Efficacy of tulathromycin in the treatment of bovine respiratory disease associated with induced Mycoplasma bovis infections in young dairy calves.
    Godinho KS; Rae A; Windsor GD; Tilt N; Rowan TG; Sunderland SJ
    Vet Ther; 2005; 6(2):96-112. PubMed ID: 16094558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf.
    Toutain PL; Potter T; Pelligand L; Lacroix M; Illambas J; Lees P
    J Vet Pharmacol Ther; 2017 Jan; 40(1):16-27. PubMed ID: 27501187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tulathromycin assay validation and tissue residues after single and multiple subcutaneous injections in domestic goats (Capra aegagrus hircus).
    Clothier KA; Leavens T; Griffith RW; Wetzlich SE; Baynes RE; Riviere JE; Tell LA
    J Vet Pharmacol Ther; 2012 Apr; 35(2):113-20. PubMed ID: 21762403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of tulathromycin after subcutaneous injection in North American bison (Bison bison).
    Bachtold K; Alcorn J; Matus J; Boison J; Woodbury M
    J Vet Pharmacol Ther; 2015 Oct; 38(5):471-4. PubMed ID: 25772094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.
    Zhao Y; Guo LL; Fang B; Liu B
    PLoS One; 2018; 13(12):e0209177. PubMed ID: 30596709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of tulathromycin in nonpregnant adult ewes.
    Washburn K; Fajt VR; Coetzee JF; Rice S; Wulf LW; Washburn S
    J Vet Pharmacol Ther; 2015 Aug; 38(4):414-6. PubMed ID: 25488837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli.
    Villarino N; Brown SA; Martín-Jiménez T
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4078-86. PubMed ID: 22585224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of experimentally induced respiratory disease on the pharmacokinetics and tissue residues of tulathromycin in meat goats.
    Smith JS; Mochel JP; Borts DJ; Griffith RW
    J Vet Pharmacol Ther; 2019 Jul; 42(4):420-429. PubMed ID: 31183876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of tulathromycin and its metabolite in swine administered with an intravenous bolus injection and a single gavage.
    Wang X; Tao YF; Huang LL; Chen DM; Yin SZ; Ihsan A; Zhou W; Su SJ; Liu ZL; Pan YH; Yuan ZH
    J Vet Pharmacol Ther; 2012 Jun; 35(3):282-9. PubMed ID: 21749408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumatic dart delivery of tulathromycin in calves results in lower antimicrobial concentrations and increased biomarkers of stress and injection site inflammation compared with subcutaneous injection.
    Coetzee JF; Kleinhenz MD; Magstadt DR; Cooper VL; Wulf LW; Van Engen NK; Smith JS; Rand N; KuKanich B; Gorden PJ
    J Anim Sci; 2018 Jul; 96(8):3089-3101. PubMed ID: 29873747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of bovine respiratory disease on the pharmacokinetics of danofloxacin and tulathromycin in different ages of calves.
    Mzyk DA; Bublitz CM; Martinez MN; Davis JL; Baynes RE; Smith GW
    PLoS One; 2019; 14(6):e0218864. PubMed ID: 31233558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and lung and muscle concentrations of tulathromycin following subcutaneous administration in white-tailed deer (Odocoileus virginianus).
    Bachtold KA; Alcorn JM; Boison JO; Matus JL; Woodbury MR
    J Vet Pharmacol Ther; 2016 Jun; 39(3):292-8. PubMed ID: 26669905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating the comparative clinical and economic consequences of tulathromycin for treatment of present or anticipated outbreaks of bovine respiratory disease in feedlot cattle in the United States.
    Nautrup BP; Van Vlaenderen I; Gasper SM; Holland RE
    J Anim Sci; 2013 Dec; 91(12):5868-77. PubMed ID: 24126273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue residue depletion and estimation of extralabel meat withdrawal intervals for tulathromycin in calves after pneumatic dart administration.
    Lin Z; He C; Magstadt DR; Cooper VL; Kleinhenz MD; Smith JS; Gorden PJ; Wulf LW; Coetzee JF
    J Anim Sci; 2019 Sep; 97(9):3714-3726. PubMed ID: 31342061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimation of tulathromycin depletion in plasma and milk after subcutaneous injection in lactating goats using a nonlinear mixed-effects pharmacokinetic modeling approach.
    Lin Z; Cuneo M; Rowe JD; Li M; Tell LA; Allison S; Carlson J; Riviere JE; Gehring R
    BMC Vet Res; 2016 Nov; 12(1):258. PubMed ID: 27863483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of tulathromycin following administration to stocker cattle with remote delivery devices.
    Rivera JD; Woolums AR; Giguère S; Johnson JT; Lutz AG; Tipton PN; Crosby WB; Hice I; Thoresen M
    J Anim Sci; 2019 Nov; 97(11):4482-4487. PubMed ID: 31583406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy of enrofloxacin to that of tulathromycin for the control of bovine respiratory disease and prevalence of antimicrobial resistance in Mannheimia haemolytica in calves at high risk of developing bovine respiratory disease.
    Crosby S; Credille B; Giguère S; Berghaus R
    J Anim Sci; 2018 Apr; 96(4):1259-1267. PubMed ID: 29471391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic characterization of susceptible and multi-drug resistant Mannheimia haemolytica isolated from high-risk stocker calves prior to and after antimicrobial metaphylaxis.
    Snyder ER; Alvarez-Narvaez S; Credille BC
    Vet Microbiol; 2019 Aug; 235():110-117. PubMed ID: 31282368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary pharmacokinetics of tulathromycin in swine. Part I: Lung homogenate in healthy pigs and pigs challenged intratracheally with lipopolysaccharide of Escherichia coli.
    Villarino N; Lesman S; Fielder A; García-Tapia D; Cox S; Lucas M; Robinson J; Brown SA; Martín-Jiménez T
    J Vet Pharmacol Ther; 2013 Aug; 36(4):329-39. PubMed ID: 23072251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of tulathromycin for the treatment of pneumonia following experimental infection of swine with Mycoplasma hyopneumoniae.
    McKelvie J; Morgan JH; Nanjiani IA; Sherington J; Rowan TG; Sunderland SJ
    Vet Ther; 2005; 6(2):197-202. PubMed ID: 16094566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.